Works matching IS 01615505 AND DT 2023 AND VI 64 AND IP 12

Results: 29

Theranostics Is Not Radiotheranostics.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 2002, doi. 10.2967/jnumed.123.266491

By:

Weber, Wolfgang Andreas

Publication type:

Article

Theranostics Is Not Radiotheranostics.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 2002, doi. 10.2967/jnumed.123.266292

By:

Weijun Wei

Publication type:

Article

Somatostatin Receptor Antagonists as a Theranostic Option in Iodine-Refractory Thyroid Carcinoma.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 2001, doi. 10.2967/jnumed.123.265639

By:

Enke, Johanna S.;
Bundschuh, Ralph A.;
Wienand, Georgine;
Reitsam, Nic G.;
Kircher, Malte;
Pfob, Christian H.;
Lapa, Constantin;
Dierks, Alexander

Publication type:

Article

One Hundred Years of the Tracer Principle.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1998, doi. 10.2967/jnumed.123.266458

By:

Hoberück, Sebastian;
Zöphel, Klaus;
Pomper, Martin G.;
Rowe, Steven P.;
Gafita, Andrei

Publication type:

Article

Performance Characteristics of a New-Generation Digital Bismuth Germanium Oxide PET/CT System, Omni Legend 32, According to NEMA NU 2-2018 Standards.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1990, doi. 10.2967/jnumed.123.266140

By:

Shin Yamagishi;
Kenta Miwa;
Shun Kamitaki;
Kouichi Anraku;
Shun Sato;
Tensho Yamao;
Hitoshi Kubo;
Noriaki Miyaji;
Kazuhiro Oguchi

Publication type:

Article

Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein α.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1941, doi. 10.2967/jnumed.123.266381

By:

Dekempeneer, Yana;
Massa, Sam;
Santens, Francis;
Navarro, Laurent;
Berdal, Marion;
Miranda Lucero, Melissa;
Pombo Antunes, Ana Rita;
Lahoutte, Tony;
Van Ginderachter, Jo A.;
Devoogdt, Nick;
D'Huyvetter, Matthias

Publication type:

Article

Clinical Characterization of [18F]T-008, a Cholesterol 24-Hydroxylase PET Ligand: Dosimetry, Kinetic Modeling, Variability, and Soticlestat Occupancy.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1972, doi. 10.2967/jnumed.123.265912

By:

Constantinescu, Cristian C.;
Brown, Terry;
Shining Wang;
Wei Yin;
Barret, Olivier;
Jennings, Danna;
Tauscher, Johannes

Publication type:

Article

[123I]CC1: A PARP-Targeting, Auger Electron--Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1965, doi. 10.2967/jnumed.123.265429

By:

Chung Ying Chan;
Zijun Chen;
Guibbal, Florian;
Dias, Gemma;
Destro, Gianluca;
O'Neill, Edward;
Veal, Mathew;
Lau, Doreen;
Mosley, Michael;
Wilson, Thomas C.;
Gouverneur, Véronique;
Cornelissen, Bart

Publication type:

Article

Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1956, doi. 10.2967/jnumed.123.265418

By:

Diaz Garcia-Prada, Clara;
Carmes, Léna;
Atis, Salima;
Parach, Ali;
Bertolet, Alejandro;
Jarlier, Marta;
Poty, Sophie;
Suarez Garcia, Daniel;
Wook-Geun Shin;
Du Manoir, Stanislas;
Schuemann, Jan;
Tillement, Olivier;
Lux, François;
Constanzo, Julie;
Pouget, Jean-Pierre

Publication type:

Article

Immuno-PET and Targeted a-Therapy Using Anti--Glypican-1 Antibody Labeled with 89Zr or 211At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1949, doi. 10.2967/jnumed.123.266313

By:

Tadashi Watabe;
Kazuya Kabayama;
Sadahiro Naka;
Ryuku Yamamoto;
Kazuko Kaneda;
Satoshi Serada;
Kazuhiro Ooe;
Atsushi Toyoshima;
Yang Wang;
Hiromitsu Haba;
Kenta Kurimoto;
Takanori Kobayashi;
Eku Shimosegawa;
Noriyuki Tomiyama;
Koichi Fukase;
Tetsuji Naka

Publication type:

Article

[18F]PI-2620 Binding Patterns in Patients with Suspected Alzheimer Disease and Frontotemporal Lobar Degeneration.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1980, doi. 10.2967/jnumed.123.265856

By:

Blazhenets, Ganna;
Soleimani-Meigooni, David N.;
Thomas, Wesley;
Mundada, Nidhi;
Brendel, Matthias;
Vento, Stephanie;
VandeVrede, Lawren;
Heuer, Hilary W.;
Ljubenkov, Peter;
Rojas, Julio C.;
Chen, Miranda K.;
Amuiri, Alinda N.;
Miller, Zachary;
Gorno-Tempini, Maria L.;
Miller, Bruce L.;
Rosen, Howie J.;
Litvan, Irene;
Grossman, Murray;
Boeve, Brad;
Pantelyat, Alexander

Publication type:

Article

Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1934, doi. 10.2967/jnumed.123.266007

By:

Galbiati, Andrea;
Dorten, Paulina;
Gilardoni, Ettore;
Gierse, Florian;
Bocci, Matilde;
Zana, Aureliano;
Mock, Jacqueline;
Claesener, Michael;
Cufe, Juela;
Büther, Florian;
Schäfers, Klaus;
Hermann, Sven;
Schäfers, Michael;
Neri, Dario;
Cazzamalli, Samuele;
Backhaus, Philipp

Publication type:

Article

Sequential and Combination Therapies of 223RaCl2 and Prostate-Specific Membrane Antigen Radioligand Therapy.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1932, doi. 10.2967/jnumed.123.266427

By:

Jadvar, Hossein

Publication type:

Article

177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior 223Ra (RALU Study).

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1925, doi. 10.2967/jnumed.123.266125

By:

Rahbar, Kambiz;
Essler, Markus;
Eiber, Matthias;
la Fougère, Christian;
Prasad, Vikas;
Fendler, Wolfgang P.;
Rassek, Philipp;
Hasa, Ergela;
Dittmann, Helmut;
Bundschuh, Ralph A.;
Pabst, Kim M.;
Kurtinecz, Milena;
Schmall, Anja;
Verholen, Frank;
Sartor, Oliver

Publication type:

Article

An Intrapatient Dosimetry Comparison of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1918, doi. 10.2967/jnumed.123.265970

By:

Rinscheid, Andreas;
Gäble, Alexander;
Wienand, Georgine;
Pfob, Christian;
Dierks, Alexander;
Kircher, Malte;
Trepel, Martin;
Weckermann, Dorothea;
Lapa, Constantin;
Bundschuh, Ralph A.

Publication type:

Article

68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1910, doi. 10.2967/jnumed.122.264827

By:

Kessler, Lukas;
Hirmas, Nader;
Pabst, Kim M.;
Hamacher, Rainer;
Ferdinandus, Justin;
Schaarschmidt, Benedikt M.;
Milosevic, Aleksandar;
Nader, Michael;
Umutlu, Lale;
Uhl, Waldemar;
Reinacher-Schick, Anke;
Lugnier, Celine;
Witte, David;
Niedergethmann, Marco;
Herrmann, Ken;
Fendler, Wolfgang P.;
Siveke, Jens T.

Publication type:

Article

Oncologic Staging with 68Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than 18F-FDG PET/CT.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1906, doi. 10.2967/jnumed.123.265751

By:

Demmert, Tristan T.;
Pomykala, Kelsey L.;
Lanzafame, Helena;
Pabst, Kim M.;
Lueckerath, Katharina;
Siveke, Jens;
Umutlu, Lale;
Hautzel, Hubertus;
Hamacher, Rainer;
Herrmann, Ken;
Fendler, Wolfgang P.

Publication type:

Article

68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1899, doi. 10.2967/jnumed.123.266079

By:

Ling Chen;
Shan Zheng;
Linying Chen;
Sunwang Xu;
Kunlin Wu;
Lingjun Kong;
Jiajie Xue;
Xiangjin Chen;
Weibing Miao;
Youzhi Zhu

Publication type:

Article

Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1895, doi. 10.2967/jnumed.123.266185

By:

Al-Toubah, Taymeyah;
Montilla-Soler, Jaime;
El-Haddad, Ghassan;
Haider, Mintallah;
Strosberg, Jonathan

Publication type:

Article

Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1889, doi. 10.2967/jnumed.123.266074

By:

Duell, Johannes;
Buck, Andreas K.;
Hartrampf, Philipp E.;
Schlötelburg, Wiebke;
Schneid, Simone;
Weich, Alexander;
Dreher, Niklas;
Lapa, Constantin;
Kircher, Malte;
Takahiro Higuchi;
Samnick, Samuel;
Serfling, Sebastian E.;
Raderer, Markus;
Rasche, Leo;
Einsele, Hermann;
Topp, Max S.;
Kosmala, Aleksander;
Werner, Rudolf A.

Publication type:

Article

First-in-Humans PET Imaging of KRASG12C Mutation Status in Non--Small Cell Lung and Colorectal Cancer Patients Using [18F]PFPMD.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1880, doi. 10.2967/jnumed.123.265715

By:

Xiang Li;
Jiajun Ye;
Jingyi Wang;
Zhiyong Quan;
Guiyu Li;
Wenhui Ma;
Mingru Zhang;
Weidong Yang;
Junling Wang;
Taoqi Ma;
Fei Kang;
Jing Wang

Publication type:

Article

ChatGPT: Can You Prepare My Patients for [18F]FDG PET/CT and Explain My Reports?

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1876, doi. 10.2967/jnumed.123.266114

By:

Rogasch, Julian M. M.;
Metzger, Giulia;
Preisler, Martina;
Galler, Markus;
Thiele, Felix;
Brenner, Winfried;
Feldhaus, Felix;
Wetz, Christoph;
Amthauer, Holger;
Furth, Christian;
Schatka, Imke

Publication type:

Article

PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1869, doi. 10.2967/jnumed.123.265874

By:

Shagera, Qaid Ahmed;
Karfis, Ioannis;
Kristanto, Paulus;
Spyridon, Sideris;
Diamand, Romain;
Santapau, Albert;
Peltier, Alexandre;
Roumeguère, Thierry;
Flamen, Patrick;
Artigas, Carlos

Publication type:

Article

Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1865, doi. 10.2967/jnumed.123.266044

By:

Laschinsky, Christina;
Theurer, Sarah;
Herold, Thomas;
Rawitzer, Josefine;
Weber, Frank;
Herrmann, Ken;
Brandenburg, Tim;
Führer-Sakel, Dagmar;
Fendler, Wolfgang P.;
Weber, Manuel

Publication type:

Article

Imaging Agents for PET of Inflammatory Bowel Disease: A Review.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1858, doi. 10.2967/jnumed.123.265935

By:

Rezazadeh, Farzaneh;
Kilcline, Aidan P.;
Viola, Nerissa T.

Publication type:

Article

61Cu-Labeled Radiotracers: Alternative or Choice?

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1855, doi. 10.2967/jnumed.123.266171

By:

Fani, Melpomeni;
Nicolas, Guillaume P.

Publication type:

Article

Ethical Considerations for Artificial Intelligence in Medical Imaging: Data Collection, Development, and Evaluation.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1848, doi. 10.2967/jnumed.123.266080

By:

Herington, Jonathan;
McCradden, Melissa D.;
Creel, Kathleen;
Boellaard, Ronald;
Jones, Elizabeth C.;
Jha, Abhinav K.;
Rahmim, Arman;
Scott, Peter J. H.;
Sunderland, John J.;
Wahl, Richard L.;
Zuehlsdorff, Sven;
Saboury, Babak

Publication type:

Article

The Hierarchy of SUVs: From Diagnostics to Therapeutics and the Pathway to Effective Theranostics.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1845, doi. 10.2967/jnumed.123.266930

By:

Hofman, Michael S.

Publication type:

Article

A Strategic Approach to Advancing Nuclear Medicine and Molecular Imaging.

Published in:

Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1843

By:

Nadel, Helen R.

Publication type:

Article

Works matching IS 01615505 AND DT 2023 AND VI 64 AND IP 12

Theranostics Is Not Radiotheranostics.

Theranostics Is Not Radiotheranostics.

Somatostatin Receptor Antagonists as a Theranostic Option in Iodine-Refractory Thyroid Carcinoma.

One Hundred Years of the Tracer Principle.

Performance Characteristics of a New-Generation Digital Bismuth Germanium Oxide PET/CT System, Omni Legend 32, According to NEMA NU 2-2018 Standards.

Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein α.

Clinical Characterization of [<sup>18</sup>F]T-008, a Cholesterol 24-Hydroxylase PET Ligand: Dosimetry, Kinetic Modeling, Variability, and Soticlestat Occupancy.

[<sup>123</sup>I]CC1: A PARP-Targeting, Auger Electron--Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer.

Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy.

Immuno-PET and Targeted a-Therapy Using Anti--Glypican-1 Antibody Labeled with <sup>89</sup>Zr or <sup>211</sup>At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma.

[<sup>18</sup>F]PI-2620 Binding Patterns in Patients with Suspected Alzheimer Disease and Frontotemporal Lobar Degeneration.

Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics.

Sequential and Combination Therapies of <sup>223</sup>RaCl<sub>2</sub> and Prostate-Specific Membrane Antigen Radioligand Therapy.

<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior <sup>223</sup>Ra (RALU Study).

An Intrapatient Dosimetry Comparison of <sup>177</sup>Lu-rhPSMA-10.1 and <sup>177</sup>Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer.

<sup>68</sup>Ga-Labeled Fibroblast Activation Protein Inhibitor (<sup>68</sup>Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial.

Oncologic Staging with <sup>68</sup>Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than <sup>18</sup>F-FDG PET/CT.

<sup>68</sup>Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study.

Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans.

Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma.

First-in-Humans PET Imaging of KRAS<sup>G12C</sup> Mutation Status in Non--Small Cell Lung and Colorectal Cancer Patients Using [<sup>18</sup>F]PFPMD.

ChatGPT: Can You Prepare My Patients for [<sup>18</sup>F]FDG PET/CT and Explain My Reports?

PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.

Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma.

Imaging Agents for PET of Inflammatory Bowel Disease: A Review.

<sup>61</sup>Cu-Labeled Radiotracers: Alternative or Choice?

Ethical Considerations for Artificial Intelligence in Medical Imaging: Data Collection, Development, and Evaluation.

The Hierarchy of SUVs: From Diagnostics to Therapeutics and the Pathway to Effective Theranostics.

A Strategic Approach to Advancing Nuclear Medicine and Molecular Imaging.